ERBB2 and breast carcinoma: Consistently, the pharmacological inhibition of CDK12 exhibited anti-proliferative effects in trastuzumab-resistant but also trastuzumab-sensitive cells, suggesting that CDK12 inhibition might serve as a replacement therapy for trastuzumab in breast cancers with amplified HER2 and CDK12 (110).